Literature DB >> 1309062

Bolus application of a novel recombinant plasminogen activator in acute myocardial infarction patients: pharmacokinetics and effects on the hemostatic system.

E Seifried1, M M Müller, U Martin, R König, V Hombach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1309062     DOI： 10.1111/j.1749-6632.1992.tb51641.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  3 in total

Review 1.  Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective.

Authors:  U Martin; B Kaufmann; G Neugebauer
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

Review 2.  Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.

Authors:  S Noble; D McTavish
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

3.  Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.

Authors:  U Martin; L Dörge; S Fischer
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.